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The relationship between the effect of aldose reductase inhibitors 
(ARIs) on the activation of the polyol pathway and on diabetic neuropathy 
has not been fully established.  To address this issue, we investigated the 
effect of epalrestat (150 mg/day), an ARI, on erythrocyte sorbitol levels as 
an index of polyol activation and on nerve function test results in 43 
patients with diabetic peripheral polyneuropathy.  After 6 months of 
epalrestat administration, erythrocyte sorbitol levels did not decrease in 
patients as a whole.  However, a decrease in erythrocyte sorbitol levels 
during epalrestat administration was significantly correlated with baseline 
erythrocyte sorbitol levels (ρ = -.47, P < .01): the higher the level at 
baseline, the greater the decrease after epalrestat treatment.  Moreover, 
the mean sorbitol level during epalrestat treatment was associated with the 
beneficial effect of epalrestat on vibration sensitivity as measured with a 
C-128 tuning fork (ρ = -.66, P < .01) and/or a pallesthesiometer TM-31A 
(ρ = .53, P < .05).  On the other hand, erythrocyte sorbitol levels did not 
reflect the prognosis of nerve conduction velocity.  These findings at 
least partly suggest a causal relationship between polyol activation and the 
development of diabetic neuropathy.  ARI treatment may be clinically 
useful in the control of polyol activation, especially in patients with 
excessive accumulation of sorbitol. 
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The polyol pathway is thought to play a major metabolic role in the 
development of diabetic neuropathy (Greene & Sima, 1992; Sima & 
Sugimoto, 1999; Zochodne, 1999; Vinik, Pittenger, McNitt, & Stansberry, 
2000).  Persistent hyperglycemia increases the polyol pathway activity in 
conjunction with accumulation of sorbitol and fructose in nerves, and this 
is accompanied by a reduction in myo-inositol uptake and inhibition of 
Na+/K+-ATPase, resulting in Na+ retention, edema, myelin swelling, 
axoglial disjunction, and nerve degeneration (Greene, Lattimer, & Sima, 
1987; Vinik, Pittenger, McNitt, & Stansberry, 2000).  Moreover, an 
increase in the activity of aldose reductase, an enzyme that catalyzes the 
reduction of glucose to sorbitol in the first step of the polyol pathway, 
may compete with nitric oxide synthase for NADPH, resulting in a 
reduction in nitric oxide.  This reduction results in reduced nerve blood 
flow and thus to nerve ischemia and nerve dysfunction (Tilton et al., 
1993; Stevens, 1995).  Therefore, the inhibition of aldose reductase can 
be expected to improve and/or prevent diabetic neuropathy. 
    Over the past two decades, many clinical trials of aldose reductase 
inhibitors (ARIs) have been performed.  However, these trials have not 
fully proven the efficacy of ARIs for the treatment of diabetic neuropathy 
(Pfeifer, Schumer, & Gelber, 1997).  One reason may be that few studies 
on humans have demonstrated any clear relationship between the effect of 
ARIs on diabetic neuropathy and on the activation of the polyol pathway.  
It is possible that ARI treatment is effective for diabetic patients only 
when the drug sufficiently suppresses the activity of the polyol pathway.  
To address this issue, we investigated the effect of epalrestat, an ARI, on 
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erythrocyte sorbitol levels as an index of polyol activation (Malone, Knox, 
Benford, & Tedesco, 1980; Hamada et al., 1995) as well as on nerve 








Adult patients with diabetic peripheral polyneuropathy were 
recruited from 5 institutions specializing in diabetes in the Hokuriku area 
of Japan.  These patients had been following fixed therapeutic regimens 
for their diabetes for the preceding 3 months with their blood glucose 
levels being kept steady.  Diabetic polyneuropathy was diagnosed 
according to the criteria proposed by Dyck (1988).  Candidates were 
excluded if they had other major diseases such as cancer, liver cirrhosis, 
and severe renal failure, or if they were pregnant.  Informed consent was 
obtained from all subjects. 
A total of 49 patients were recruited for this study.  During the study 
period, 5 patients were lost to follow up, and one patient discontinued 
epalrestat treatment due to vomiting.  The background of the 43 patients 
who completed the study is given in Table 1.  The mean duration of 
diabetes was 13.6 years, and 93% of the patients were under medical 
treatment with oral hypoglycemic agents or insulin.  Retinopathy was 
diagnosed in 65% and nephropathy in 44%.  Before epalrestat 
administration, 91% of the patients had at least one subjective symptom of 
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peripheral polyneuropathy, with numbness being the most common 
symptom (88% of the patients). 
 
2.2. Study protocol 
 
Epalrestat was administered to subjects for at least 6 months.  The 
dosage was 150 mg/day: one 50-mg Kinedak tablet (Ono Pharmaceutical 
Co., Osaka, Japan) was orally administered three times daily before each 
meal.  No drugs which might have a possible effect on neuropathy, 
including vitamin B12, peripheral vasodilators, analgesics, 
anti-convulsants, and Chinese herbal remedies, were administered at any 
time during the study period. 
Vibration sensitivity was measured with a C-128 tuning fork and/or a 
pallesthesiometer TM-31A at the medial malleolus.  Motor and sensory 
nerve conduction velocities (MNCV and SNCV) were determined at the 
median nerve.  All nerve function tests were performed under the same 
conditions before epalrestat administration, and after 6 months of drug 
administration. 
Blood samples for the measurements of erythrocyte sorbitol and 
hemoglobin A1c (HbA1c) levels were obtained the morning after an 
overnight fast, before and after epalrestat administration.  Erythrocyte 
sorbitol levels were determined with an enzymatic assay as previously 
described (Malone, Knox, Benford, & Tedesco, 1980), and expressed as 
nmol/g hemoglobin (Hb). 
. 
 
2.3. Statistical analyses 
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Data are presented as means ± S.D.  The Wilcoxon’s signed-rank 
test was used to compare the data before and after epalrestat 
administration.  Correlations were assessed with the aid of Spearman’s 
rank order correlation coefficient.  Statistical significance was defined as 
P < .05.  All analyses were performed with the computer program 
StatView, version 5.0 (SAS Institute, Cary, NC). 
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At baseline, erythrocyte sorbitol levels tended to correlate with 
HbA1c levels (ρ = .32, P = .056).  However, this correlation completely 
disappeared after 6 months of epalrestat administration (ρ = .02, P = .90), 
indicating that treatment with epalrestat affected erythrocyte sorbitol 
levels.  Interestingly, the higher the erythrocyte sorbitol level at baseline, 
the greater the decrease after epalrestat administration (Fig. 1; ρ = -.47, P 
= .002).  Although HbA1c levels slightly decreased from 7.4% to 7.2% 
after epalrestat administration, erythrocyte sorbitol levels did not 
significantly change in patients as a whole (Table 2).  In addition, 
epalrestat administration did not affect any nerve function except for 
vibration sensitivity as measured with a TM-31A.  All function test 
results, however, improved in approximately half of the patients (data not 
shown).  Thus, with respect to sorbitol levels and nerve function, both 
responders and non-responders to epalrestat may have been present. 
We next examined whether the effect of epalrestat on erythrocyte 
sorbitol levels might reflect changes in nerve function during epalrestat 
treatment.  Table 3 shows the correlation of erythrocyte sorbitol level 
with percentage change in nerve function test results.  Erythrocyte 
sorbitol levels at baseline significantly correlated with percentage change 
in vibration sensitivity test results as measured with a C-128.  
Additionally, sorbitol levels after treatment tended to correlate with 
percentage changes in C-128 and TM-31A.  Furthermore, the mean 
sorbitol level during treatment significantly correlated with percentage 
changes in C-128 and TM-31A.  With regard to HbA1c levels, a similar 
significant correlation with vibration test results was not found (Table 4).  
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On the other hand, nerve conduction velocities did not correlate with these 
erythrocyte sorbitol levels at all, whereas SNCV correlated with HbA1c 
levels after epalrestat administration.  Thus, erythrocyte sorbitol levels 
measured during epalerestat treatment might partly reflect changes in 
nerve function.
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In the present study, 6-month treatment with epalrestat did not 
decrease erythrocyte sorbitol levels in patients as a whole.  However, a 
decrease in erythrocyte sorbitol levels during epalrestat administration 
significantly correlated with initial baseline erythrocyte sorbitol levels.  
Moreover, the mean sorbitol level during epalrestat treatment was 
associated with the prognosis of vibration sensitivity.  To the best of our 
knowledge, this is the first study to demonstrate a correlation between 
erythrocyte sorbitol levels and changes in nerve function tests during ARI 
administration. 
Nakayama et al. (2001) have reported that 24 weeks of epalrestat 
treatment ameliorated papillary light reflex and F-wave latency, but not 
nerve conduction velocity, in patients with mild diabetic neuropathy.  On 
the other hand, ARI, zenarestat, has shown to reduce both erythrocyte and 
nerve sorbitol contents in a dose-dependent manner and that this sorbitol 
suppression was accompanied by significant improvements in the slowing 
down of nerve conduction velocity and the loss of small myelinated nerve 
fibers in patients with diabetic polyneuropathy (Greene, Arezzo, & Brown, 
1999).  Therefore, the effects of zenarestat, not only on erythrocyte 
sorbitol levels, but also on nerve function, are seemingly greater than 
those of epalrestat found in Nakayama’s and our studies.  However, this 
difference in treatment effect may be caused by several factors, including 
the duration of ARI treatment, the level of glycemic control, and the 
severity of neuropathy in the participants.  In the zenarestat study, the 
effects on nerve function were evaluated after 52 weeks of zenarestat 
administration.  Twenty-four weeks of epalrestat treatment might be too 
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short to investigate the effect on nerve conduction velocity.  Moreover, 
HbA1c levels at baseline were less than 7.0% in 50% of our subjects, 
whereas patients with good glycemic control were excluded in the 
zenarestat study.  Furthermore, the other factors may have greater effects, 
because a clinical study (Brown et al., 2004) has demonstrated that the 
changes of nerve function test results during 12 months were independent 
of baseline HbA1c stratification in a large diabetic peripheral neuropathy 
population.  It has been speculated that the ability to improve or preserve 
nerve function may be limited by disease severity (Hotta et al., 2001).  
The zenarestat study targeted only patients with mild or moderate 
neuropathy and excluded patients with advanced nerve damage.  
Subjects with relatively severe neuropathy were included in the present 
study, resulting in a high percentage of patients with retinopathy and/or 
nephropathy.  Thus, regarding erythrocyte sorbitol levels and nerve 
function, both ARI responders and non-responders appear to be present.  
Asano et al. (2004) have reported that the daily administration of another 
ARI fidarestat suppressed erythrocyte sorbitol levels in diabetic patients 
much more potently than treatment with epalrestat.  Further studies are 
needed to evaluate the differences of treatment effects among ARIs.
    In placebo-controlled double-blind studies (Goto, Hotta, Shigeta, 
Sakamoto, & Kikkawa, 1995; Hotta et al., 2001), ARI treatment has been 
reported to improve not only nerve conduction velocity but also various 
subjective symptoms of diabetic neuropathy.  Although the present study 
did not employ a controlled design, numbness was improved in 78% of 
the patients during the study period, a finding that is compatible with 
results reported in a previous controlled study with epalrestat (Goto, Hotta, 
Shigeta, Sakamoto, & Kikkawa, 1995).  Because nerve function test 
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results are known to bear no relationship to the severity of symptoms 
(Greene et al., 1981), it is probable that ARI treatment can improve 
subjective symptoms without any effect on nerve function.  Further 
placebo-controlled studies are needed to clarify whether erythrocyte 
sorbitol levels are associated with the efficacy of ARIs in improving 
subjective symptoms of diabetic neuropathy. 
In conclusion, mean erythrocyte sorbitol levels during epalerestat 
treatment could reflect the prognosis of vibration sensitivity in patients 
with diabetic peripheral polyneuropathy.  Our findings support the 
theory that increased activity of the polyol pathway plays a role in the 
development of diabetic neuropathy.  ARI treatment may be clinically 
useful in the control of polyol activation, at least in patients with 
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Correlation between baseline level and change in erythrocyte sorbitol 
level during epalrestat treatment.  The higher the erythrocyte sorbitol 
level was at baseline, the greater the decrease after 6 months of epalrestat 
administration (ρ = -.47, P = .002). 
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    Men 19 (44)
    Women 24 (56)
Age (years) 64.8 ± 9.7
Type of diabetes
    Type 1 2 (5)
    Type 2 41 (95)
Duration of diabetes (years) 13.6 ± 7.2
Treatment
    Diet 3 (7)
    Oral hypoglycemic agents 18 (42)
    Insulin 22 (51)
Retinopathy 28 (65)
Nephropathy 19 (44)
Data are expressed as n (%), or means ± S.D.




Changes in erythrocyte sorbitol and HbA1c levels, and nerve function tests
n Baseline 6 months later
Erythrocyte sorbitol level (nmol/g Hb) 43 26.3 ± 12.9 28.5 ± 15.3
HbA1c (%) 37 7.4 ± 1.1 7.2 ± 1.1*
C-128 (s) 24 7.1 ± 3.0 7.5 ± 2.3
TM-31A (μm) 19 52.4 ± 36.4 33.1 ± 17.0*
MNCV (m/s) 34 49.2 ± 6.3 49.5 ± 6.8
SNCV (m/s) 19 49.0 ± 8.0 45.2 ± 13.2
Data are means ± S.D.  *P <.05 vs. baseline.




Correlation of erythrocyte sorbitol level with percentage change in the
nerve function tests before and after 6 months of epalrestat administration
Nerve function tests ρ P








Mean C-128 -.66 < .01








Correlation of HbA1c level with percentage change in the nerve
function tests before and after 6 months of epalrestat administration
Nerve function tests ρ P




6 months later C-128 .13 .56
TM-31A .04 .87
MNCV -.02 .93
SNCV -.65 < .05
Mean C-128 -.21 .37
TM-31A .26 .29
MNCV .12 .52
SNCV -.49 .08
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